Jun 21, 2024, 07:47
Blood Cancers Today – Is reduced-duration venetoclax in AML effective?
Blood Cancers Today shared a post on X:
“Is reduced-duration venetoclax in AML effective?
A study presented at EHA2024 by Christophe Willekens, MD, of Gustave Roussy, compares reduced venetoclax exposure of seven days with standard continual venetoclax exposure.”
Read further.
Source: Blood Cancers Today/X